Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effect of CR8020 and CR6261 in Hospitalized Patients With Influenza A Infection
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2017
Price : $35 *
At a glance
- Drugs CR 8020 (Primary) ; Diridavumab (Primary)
- Indications Influenza A virus infections
- Focus Therapeutic Use
- Sponsors Janssen Vaccines and Prevention
- 03 Aug 2017 This trial has been discontinued in Belgium.
- 03 Mar 2014 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov record.
- 07 Jan 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov